We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

52 hedge funds and large institutions have $32.2M invested in Enzo Biochem, Inc. in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $27.5M → $32.2M (+$4.65M)

17% less funds holding

Funds holding: 6352 (-11)

50% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 20

69% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 16

91% less call options, than puts

Call options by funds: $9K | Put options by funds: $95K

Holders
52
Holders Change
-11
Holders Change %
-17.46%
% of All Funds
1.69%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
10
Reduced
20
Closed
16
Calls
$9K
Puts
$95K
Net Calls
-$86K
Net Calls Change
-$32K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$8.44M
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$4.97M -$25.7K -10,837 -0.5%
Millennium Management
3
Millennium Management
New York
$3.84M +$35.6K +15,000 +1%
ClearBridge Investments
4
ClearBridge Investments
New York
$3.04M -$184K -77,502 -6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.06M +$204K +86,091 +12%
BIT
6
BlackRock Institutional Trust
California
$1.98M -$193K -81,365 -9%
CCM
7
Corsair Capital Management
New York
$1.57M +$185K +78,143 +14%
Renaissance Technologies
8
Renaissance Technologies
New York
$715K +$60.2K +25,400 +10%
CCT
9
Chemung Canal Trust
New York
$649K +$19.5K +8,238 +3%
BCM
10
Bridgeway Capital Management
Texas
$605K
LMF
11
LMR Master Fund
Cayman Islands
$435K -$64.7K -27,304 -14%
Goldman Sachs
12
Goldman Sachs
New York
$425K -$1.49K -628 -0.4%
AA
13
Ancora Advisors
Ohio
$344K +$196K +82,808 +154%
Morgan Stanley
14
Morgan Stanley
New York
$289K +$24.4K +10,285 +10%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$288K -$25.4K -10,702 -9%
CFB
16
Cullen/Frost Bankers
Texas
$259K
Verition Fund Management
17
Verition Fund Management
Connecticut
$252K +$237K +99,883 New
Northern Trust
18
Northern Trust
Illinois
$251K -$31.3K -13,217 -12%
BFA
19
BlackRock Fund Advisors
California
$245K +$17.9K +7,560 +8%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$218K
Charles Schwab
21
Charles Schwab
California
$185K -$12.2K -5,140 -7%
KCM
22
Kempner Capital Management
Texas
$176K
GCP
23
GSA Capital Partners
United Kingdom
$173K -$8.77K -3,700 -5%
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$143K
Two Sigma Investments
25
Two Sigma Investments
New York
$65K +$61K +25,744 New

ENZ Hedge Fund Activity: Q3 2013 in Review

52 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2013, worth a combined $32.2M — up 17% from $27.5M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ENZ and 5 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 10 added.

The largest buyer was Verition Fund Management, opening a new position worth an estimated $237K. The largest seller was Ameriprise, cutting an estimated $294K.

  • 52 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2013, down from 63 in Q2 2013.
  • Funds reported $32.2M of Enzo Biochem, Inc. stock for Q3 2013, up 17% quarter-over-quarter.
  • 5 funds opened new Enzo Biochem, Inc. positions in Q3 2013 and 16 closed out, a net change of -11 holders.
  • The largest Enzo Biochem, Inc. buyer in Q3 2013 was Verition Fund Management, an estimated $237K added.
  • The largest Enzo Biochem, Inc. seller in Q3 2013 was Ameriprise, an estimated $294K sold.

Based on aggregated 13F filings for Q3 2013.